Vazegepant hydrochloride
Vazegepant hydrochloride is a novel intranasal CGRP receptor antagonist for the acute treatment of migraine, supported by positive Phase II/III clinical data. It is utilized in preclinical research to investigate CGRP-mediated pathways in both in vitro binding assays and in vivo models of migraine and pain.
Product Specifications
CAS Number
1414976-20-7
Product Name Alternative
CGRP Receptor, CGRP, CGRPReceptor, COVID-19, BHV 3500, BHV3500, BHV-3500, Calcitonin gene-related peptide receptor, Inhibitor, gepant, inflammation, intranasal, inhibit, migraine, receptor, Zavegepant, soluble, Vazegepant, Vazegepant HCl, Vazegepant hydrochloride, Vazegepant Hydrochloride
Field of Research
Neuroscience, Pharmacology & Drug Discovery
Purity
98.93% (May vary between batches)
Solubility
DMSO:30 mg/mL (44.42 mM)
Smiles
Cl.CN1CCC (CC1) N1CCN (CC1) C (=O) [C@@H] (Cc1cc (C) c2[nH]ncc2c1) NC (=O) N1CCC (CC1) c1cc2ccccc2[nH]c1=O
Molecular Formula
C36H47ClN8O3
Molecular Weight
675.3
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
